Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Jack W. Singer, Angela Fleischman, Suliman Al-Fayoumi, John O. Mascarenhas, Qiang Yu, Anupriya Agarwal

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)33416-33439
Number of pages24
JournalOncotarget
Volume9
Issue number70
DOIs
StatePublished - Sep 1 2018

Keywords

  • Cancer
  • Inflammatory diseases
  • Interleukin-1 receptor associated kinase (IRAK1)
  • MyD88
  • Pacritinib

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy'. Together they form a unique fingerprint.

  • Cite this

    Singer, J. W., Fleischman, A., Al-Fayoumi, S., Mascarenhas, J. O., Yu, Q., & Agarwal, A. (2018). Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget, 9(70), 33416-33439. https://doi.org/10.18632/oncotarget.26058